



EPHA 2018

UNIVERSAL ACCESS AND AFFORDABLE  
MEDICINES FORUM

---

**TRAILBLAZERS**

ROUTES TO BETTER AND AFFORDABLE  
MEDICINES BY 2025

---

**PROGRAMME**

---

20 November 2018

---

Scotland House, Brussels

---

 | [#Trailblazers2025](https://twitter.com/Trailblazers2025)

---

 **epria** european  
public health  
alliance



# JOIN THE DEBATE!

Share your questions and comments  
with us throughout the day.

WiFi password: scotland

#Trailblazers2025



**Co - funded by  
The health Programme  
of the European Union**

The European Public Health Alliance has received funding under an operating grant from the European Union's Health Programme (2014-2020). The content of this publication represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.



# WELCOME TO THE 3<sup>RD</sup> EPHA UNIVERSAL ACCESS AND AFFORDABLE MEDICINES FORUM!

---

In organizing the first forum, three years ago, EPHA's ambition was to introduce a new, meaningful and genuine dialogue around pharma and medicines policy in Brussels and beyond. With “[Healthy Innovation for All](#)”, EPHA partnered with the Polish Government, the first time a civil society organization joined forces with an EU Member State to put all of the issues concerning pharmaceutical companies and medicines policies on the agenda.

The first Forum took place a few months after the groundbreaking June 2016 Council Conclusions on pharmaceutical systems in the EU and the Member States, the culmination of the disruptive Dutch Presidency of the EU. After this point, the public discourse around pharmaceuticals would never be the same again, as with these bold conclusions, EU Health Ministers acknowledged, for the first time ever, a series of imbalances in the pharmaceutical systems in the EU. In other words, they made it clear that the current pharmaceutical business model was no longer sustainable and should be reviewed. The Conclusions were only the beginning, coinciding with a series of unprecedented political developments at national, European and global level.

## KEY MOMENTS

---

- The birth, “growing up” and expansion of regional initiatives of intergovernmental collaboration to tackle the issue of affordable access to meaningful innovation such as Beneluxa, the Valletta Declaration Group of countries and others (2015-ongoing)
- The successful negotiations on Orkambi (May 2017) and Spinraza (August 2018) within Beneluxa
- The questioning of the impact and suitability of intellectual property (IP)-related incentives in drug development (2016-ongoing)
- The European Commission proposal to introduce a supplementary protection certificate (SPC) waiver in the EU (May 2018)
- The critical review of the orphan drugs legislation (ongoing)
- The first ever meeting between the payers’ community and the European Medicines Agency (EMA) (September 2017)
- The controversial adaptive pathways pilot project (2014-2016) and the launch of the Priority Medicines Scheme (PRIME, 2016) by the EMA
- The European Commission proposal on Health Technology Assessment (HTA) collaboration (January 2018)
- The publication of the United Nations High-Level Panel (UNHLP) Report on Access to Medicines (September 2016)
- The European Ombudsman’s Strategic Inquiry into pre-submission activities organised by the EMA (July 2017-ongoing)
- The start of round-table discussions between EU Health Ministers and European Heads of pharmaceutical companies (May 2016-ongoing)
- The World Health Organization Fair Pricing Forum (May 2017)
- The spotlight on the role of national medicines agencies and the EMA in the access to medicines debate (ongoing)
- The publication of the Drug Pricing Scenarios Project by Belgian HTA (KCE) and Dutch HTA (ZIN) agencies (June 2016)
- The need to map the public support for medical R&D and to guarantee a fair return on this multi-faceted investment (ongoing)



Unquestionably, much has happened in the past three years as pharmaceutical policy has moved up the political agenda in response to growing concerns about the impact of high drugs prices on national health systems and patients' equitable access to treatments.

Often, EPHA and our members have been centre stage on many of these occasions, forging new coalitions, highlighting the public health perspective in the debate and bringing all stakeholders together to discuss solutions and new ways of working. EPHA was also central to establishing the European Alliance for Responsible R&D and Affordable Medicines, gathering consumer, patient and public health organisations at local, national and European level to call for the creation of a medical R&D system driven by public health needs and delivering medicines that are universally accessible and affordable. “[Game Changers](#)”, the 2017 edition of the EPHA Universal Access and Affordable Medicines Forum, provided ideas and input to the work of the Bulgarian and Austrian Presidencies of the EU (2018) to maintain the momentum, following the landmark outcomes of the Dutch Presidency.

EPHA's 2018 Forum, “[Trailblazers: Routes to better and affordable medicines by 2025-what do we want from our future medicines policy?](#)”, convenes key stakeholders and influencers once again to take stock of these developments, to distill them and look forward to what should happen next, following the renewal of the European Commission and the European Parliament elections next year, at this crucial moment for pharmaceutical policy.



# ABOUT EPHA'S UNIVERSAL ACCESS AND AFFORDABLE MEDICINES ADVOCACY

---

EPHA's Universal Access and Affordable Medicines campaign promotes transparency, accountability and the public interest in the field of pharmaceuticals in line with the priorities of our members most active in this field. We aim to guarantee better and affordable medicines for Europe by questioning and calling for reforms to the current pharmaceutical business model to ensure better access to medicines for all.

Developed in response to the growing risk to patients and healthcare systems from the increasing costs of medicines, our advocacy is driven by our members' interests, complimenting their work at local, national and European level. Through regular meetings, working groups and conferences we exchange views with other stakeholders and develop positions, often in common, on key aspects of medicines policy, a small sample of which you can find at the end of this programme.

EPHA collaborates with several governments in Europe to drive the access to medicines debate forward and to ensure that all voices, including those of patients, are heard. As the only representative of expert civil society, in May 2017, EPHA took part in the 3rd round-table discussion between Health Ministers and European Heads of pharmaceutical companies in Valletta, Malta. EPHA is now a member of the High-Level Group mandated by the Health Ministers to prepare the agenda for the annual round-table discussions.

"**Healthy Innovation for All**", the EPHA 2016 Universal Access and Affordable Medicines Forum (November 2016) was the first ever pharma-related, civil society event to take place under the auspices of an EU Member State (Poland). The second forum, "**Game Changers for better and affordable medicines for Europe**", the following year under



the auspices of the incoming Bulgarian Presidency of the EU provided input to the Presidency's work by fostering an honest discussion around the hottest topics in pharmaceutical policy.

EPHA also contributes to the debate at global level, partnering in June 2017 with the Collaboration for Research Integrity and Transparency (CRIT) of Yale University to co-host an international conference in New Haven, Connecticut titled **"Ensuring Safety, Efficacy, and Access to Medical Products in the Age of Global Deregulation."** EPHA is regularly invited by the Organisation for Economic Cooperation and Development (OECD) and the World Health Organization (WHO) to contribute to ongoing access to medicines policy debates.

EPHA's members view Health Technology Assessment (HTA) as a powerful ally of patients and health care systems. As one of the few members of the HTA Stakeholder Pool, EPHA helps to shape the future of European collaboration in the field of HTA, publishing **our recommendations** to improve the European Commission's proposal in July this year. Committed to supporting the work of the European Medicines Agency (EMA) and defending its independence, **EPHA's recommendations** calling for more transparent scientific advice by the EMA to the pharmaceutical sector, are endorsed by numerous organisations including two national Health Technology Assessment Agencies (KCE and LBI-HTA) and by the Belgian Social Insurance Agency (RIZIV/INAMI). EPHA also actively participates in the Patient and Consumer Working Party (PCWP) of the EMA.

EPHA is a long-standing partner of the European Health Forum Gastein (EHFG), joining forces with Open Society Foundations and the European Alliance for Responsible R&D and Affordable Medicines in 2018 and the European Public Health Association (EUPHA) in 2016 and 2017 to organize agenda-setting sessions on different aspects of the access to medicines debate.

Finally, EPHA is a founding member and hosts the secretariat of the European Alliance for Responsible R&D and Affordable Medicines, an informal coalition of more than 80 European and national organisations working exclusively on access to medicines issues.

# TRAILBLAZERS: routes to better and affordable medicines by 2025

## What do we want from our future medicines policy?

---

**09:00-09:30**      **REGISTRATION AND COFFEE**

---

**09:30-09:45**      **WELCOME AND INTRODUCTION**

Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines, European Public Health Alliance (EPHA) [@YNatsis](#), [@EPHA\\_EU](#)

---

**09:45-11:15**      **ACCESS TO MEDICINES IN EUROPE: ARE PAYERS FACING A DEAD END?**

*Open discussion moderated by Tania Dussey-Cavassini [@TaniaDussey](#)*

- Jo De Cock, CEO, National Institute of Health and Disability Insurance (RIZIV/INAMI), Belgium [@RIZIV\\_INAMI](#), [@INAMI\\_RIZIV](#)
  - Marjan Suselj, General Director, Health Insurance Institute of Slovenia (HIIS)
  - Evert Jan van Lente, Director EU-Affairs, AOK-Bundesverband, Germany [@AOK\\_Politik](#)
  - Adrian van den Hoven, Director General, Medicines For Europe [@medicinesforEU](#)
- 

**11:15-11:30**      **COFFEE BREAK**

---

**11:30-13:00**      **THOUGHT LEADERS FORUM: WHERE DO WE STAND AND WHERE IS MEDICINES POLICY IN EUROPE HEADING?**

*Open discussion moderated by Tania Dussey-Cavassini*

- Paola Testori Coggi, Italian Medicines Agency (AIFA) [@Aifa\\_ufficiale](#)
- Clemens Auer, Special Envoy for Health, Federal Ministry of Labour, Social Affairs, Health and Consumer Protection, Austria
- Carlo Maria Marengi, Legal Attaché for Intellectual Property and Trade issues, Holy See [@HolySeeUN](#), [@pontifex](#)
- Ri De Ridder, President, Médecins du Monde, Belgium [@MdMBelgique](#)
- Nathalie Moll, Director General, European Federation of Pharmaceutical Industries and Associations, EFPIA [@NathalieMoll](#), [@EFPIA](#)

---

**13:00-14:00**      **LUNCH**

---

**14:00-15:30**      **PUBLIC INVESTMENT IN MEDICAL R&D IN EUROPE:  
WHY, WHEN, HOW & WHO?**

*Open discussion moderated by Tania Dussey-Cavassini*

- Marie-Paule Kieny, Director of Research, French National Institute of Health and Medical Research (INSERM), France [@inserm](#)
- Stefano Vella, Director, National Center for Global Health, Istituto Superiore di Sanita (ISS), Italy [@stefano\\_vella](#), [@istsupsan](#)
- Stuart Pritchard, EU & Public Affairs Manager, Wellcome Trust [@wellcometrust](#)
- Viviana Galli, Coordinator, European Alliance for Responsible R&D and Affordable Medicines [@Vivivovi](#)

---

**15:30-15:45**      **COFFEE BREAK**

---

**15:45-17:15**      **THE INNOVATION ECOSYSTEM IN EUROPE: HOW WILL IT  
LOOK LIKE IN 2025?**

*Open discussion moderated by Tania Dussey-Cavassini*

- Rufus Pollock, Entrepreneur, founder & president of Open Knowledge [@rufuspollock](#), [@OKFN](#)
- Jan Van den Bossche, Partner, Fund+, Belgium
- Zoltán Kaló, Professor of Health Economics, Eötvös Loránd University (ELTE), Hungary
- Carin Uyl-de Groot, Professor of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Netherlands [@ESHPM\\_EUR](#)

---

**17:15-18:00**      **NETWORKING RECEPTION**



## WELCOME AND INTRODUCTION

---

09:30-09:45

---



### Tania Dussey-Cavassini

**Moderator**

Tania Dussey-Cavassini combines 27 years of experience in global health, diplomacy, business consulting, executive education and law enforcement with strong exposure to companies ranging from global services, life sciences, consumers products to heavy industries. Tania serves on the Board of Directors of the Here-Geneva Foundation. She is member of the Advisory Board of The Women's Brain Project.



### Yannis Natsis

**Policy Manager for Universal Access and Affordable Medicines, EPHA, [@YNatsis](#), [@EPHA\\_EU](#)**

Yannis currently leads the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). Before joining EPHA in January 2016, he worked at the European Parliament, the Greek Ministry of Foreign Affairs, the UN and the private sector in Brussels



and Athens. Between 2013-2015, Yannis was Advocacy Advisor for the TransAtlantic Consumer Dialogue (TACD) focusing on access to medicines. Between 2006-2010, he was an investigative reporter for Greece's award-winning TV news programme "Fakeli," and a contributor to the Greek daily "Kathimerini". Yannis is committed to promoting transparency, accountability and protecting the public interest in health policy. He contributes to the discussions on regulatory developments in pharmaceuticals, medical innovation and patients' access to treatment. Since January 2018, he has been a member of the Board of the European Health Forum Gastein (EHFG).

## ACCESS TO MEDICINES IN EUROPE: ARE PAYERS FACING A DEAD END?

---

09:45-11:15



---

Jo De Cock

CEO, National Institute of Health and Disability Insurance  
(RIZIV/INAMI), Belgium [@RIZIV\\_INAMI](#), [@INAMI\\_RIZIV](#)

Jo De Cock is CEO of the National Institute of Health and Disability Insurance since 1995. He started his professional experience as a research assistant at the Catholic University of Louvain, and continued his career at the Center for political, economic and social studies as researcher and political advisor. From the mid-eighties until the beginning of the nineties he worked as a Deputy Director and Counselor of Social Affairs in the office of the Belgian Prime Minister. Before taking



his role at RIZIV/INAMI, Mr De Cock was adjunct general administrator of the National Social Security Office (1993-1995).



---

## Marjan Sušelj

**General Director, Health Insurance Institute of Slovenia (HIIS)**

Marjan Suselj has been the General Director of the Health Insurance Institute of Slovenia (HIIS) since September 2017. Between 2010 and 2017 he managed the HIIS regional unit of Ljubljana. Prior to that, Marjan was involved in numerous ICTs and other innovations projects in the health care and health insurance domain. He managed the introduction of the national health Insurance card programme and its on-line upgrade. Mr Suselj is one of the founders of the European Health Telematics Association (EHTEL) and has represented Slovenia in the Technical Commission at CA.SS.TM. responsible for coordination of the social security issues at EU level.



---

## Evert Jan van Lente

**Director EU-Affairs, AOK-Bundesverband, Germany @AOK\_Politik**

Mr van Lente is a health economist and Director EU-Affairs of the AOK-Bundesverband, Germany, the leading statutory health insurance Organisation with 26 million insured persons in all states of Germany.

Mr van Lente has been an international consultant for health financing and organization for 20 years and a lecturer at the University Ulm and the Bonn-Rhein-Sieg University of Applied Science.



---

## Adrian van den Hoven

Director General, Medicines For Europe [@medicinesforEU](#)

Adrian van den Hoven joined Medicines for Europe as Director General in September 2013, where he works towards stimulating competition in off-patent medicine markets, fostering market access for generic, biosimilar and value added medicines, and supporting policy measures for sustainable pricing. Former Deputy-Director General of BusinessEurope, Mr van den Hoven previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor).

# THOUGHT LEADERS FORUM: WHERE DO WE STAND AND WHERE IS MEDICINES POLICY IN EUROPE HEADING?

---

11:30-13:00



---

## Paola Testori Coggi

Italian Medicines Agency (AIFA) [@Aifa\\_ufficiale](#)

Paola Testori Coggi has been President of the Committee for Price and Reimbursement of the Italian Agency for Pharmaceuticals (AIFA) from 2015 to 2018 and is currently continuing her collaboration with the Agency. Ms Testori Coggi was Director General for Health and Consumers of the European Commission from 2010 to 2014, having joined the European Commission in 1983 in the area of environment and later life sciences research.



Ms Testori Coggi is a biologist from the University of Milan with a Master degree in Ecotoxicology.



---

## Clemens Auer

**Special Envoy for Health, Federal Ministry of Labour, Social Affairs, Health and Consumer Protection, Austria**

Clemens Auer is the Special Envoy for Health for the Austrian Federal Ministry for Labour, Social Affairs, Health and Consumer Protection, focusing on international, multilateral and bilateral health policy issues, particularly WHO (nominated member of the Executive Board), the United Nations, the EU, the OECD and the European Observatory. Former Head of Cabinet of Minister of Health Maria Rauch-Kallat, he was Director General for the Austrian health system and international affairs from September 2005 until September 2018. In this capacity, he worked on almost all major healthcare reform projects in Austria since 2003, and was also Co-Chair of the EU eHealth Network. He is also the President of the European Health Forum Gastein and a member of the Advisory Board of the European Forum Alpbach.



---

## Carlo Maria Marengchi

**Legal Attaché for Intellectual Property and Trade Issues, Holy See, [@HolySeeUN](#), [@pontifex](#)**

Carlo Maria Marengchi is the Legal Advisor of the Permanent Mission of the Holy See to the United Nations and to the specialized institutions in Geneva. A professor of techniques and principles of negotiation at Webster University in Geneva, he has collaborated with Cambridge University's St. Edmund College, and is the author of articles and essays on international law and international organization related to health, commerce,



intellectual property, labour and human rights. Mr Marengi obtained a doctorate in international law (2014), and holds a diploma from the European College of Parma in Advanced European Studies (2009) and a Master in Hautes Etudes Européennes at the “Suor Orsola Benincasa” University of Naples (2010).



---

## Ri De Ridder

**President, Médecins du Monde, Belgium, [@MdMBelgique](#)**

Ri De Ridder is the President of Médecins du Monde Belgium. He started his career in 1976 as a doctor and was part of the foundation of the first district health centres in Flanders. From 1997 Mr De Ridder worked as advisor and deputy chief of staff for a number of successive Ministers of Health and Social Affairs. He has led the Health Care Insurance department of the National Institute of Health and Disability Insurance for 12 years.



---

## Nathalie Moll

**Director General, European Federation of Pharmaceutical Industries and Associations, EFPIA [@NathalieMoll](#), [@EFPIA](#)**

Nathalie Moll joined the European Federation of Pharmaceutical Industries and Associations (EFPIA) as Director General in April 2017. Prior to joining EFPIA, between 2010 and 2017 Ms Moll was the Secretary General of EuropaBio, ranked as the most effective European Trade Association in Brussels in 2013. She spent over 20 years working for the biotech industry at EU and national level in associations and corporate positions and held the position of Chair and Vice Chair of the International Council of Biotech Associations (ICBA).



In 2013, she won the Technovisionaries Women Innovation Award organised by Women & Technologies®, while in 2009, Ms Moll and the Green Biotech Team of EuropaBio were presented with the Leadership and Excellence in Advancing Ag-Biotech and Food Issues Award. Nathalie was also named one of the 15 leading women in biotech in Europe in 2017.

Ms Moll holds an Honours Degree in Biochemistry and Biotechnology from St Andrews University, Scotland.

## PUBLIC INVESTMENT IN MEDICAL R&D IN EUROPE: WHY, WHEN, HOW & WHO?

---

14:00-15:30



---

### Marie-Paule Kieny

**Director of Research, French National Institute of Health and Medical Research (INSERM), France [@Inserm](#)**

Dr Marie-Paule Kieny is currently Director of Research at Inserm (Institut national de la santé et de la recherche médicale) in Paris. She is the Chair of the Board of the Drugs for Neglected Diseases Initiative (DNDi, Geneva, Switzerland) and of the Medicines Patent Pool Foundation (MPPF, Geneva, Switzerland), as well as a member of the Board of the Global Antibiotic Research and Development Partnership (GARDP, Geneva, Switzerland) the Human Vaccine Project (HVP, New York, USA) and a Non-Executive Independent Director of bioMérieux (Lyon, France). Formerly Assistant Director-General for Health Systems and Innovation at the World Health Organization, Dr Kieny has been awarded the



title of Chevalier dans l'Ordre National de la Légion d'honneur (Knight in the National Order of the Legion of Honour, France) in 2016, and of Chevalier de l'Ordre National du Mérite, au titre du Ministère de la Recherche (Knight of the National Order of Merit, under the Ministry of Research, France) in 2000. She was the recipient of the International Inserm Prize in 2017; the Génération 2000-Impact Médecin Prize in 1994 and the Innovation Rhône-Poulenc Prize in 1991.



---

## Stefano Vella

Director, National Center for Global Health, Istituto Superiore di Sanità (ISS), Italy [@stefano\\_vella](#), [@istsupsan](#)

Dr Stefano Vella has been Chair of the International Aids Society (IAS), and the Scientific Advisor of the Italian Cooperation Department (Ministry of Foreign Affairs) in different African countries. Formerly President of the Italian Medicines Agency (AIFA), he is currently the Director of the Italian Centre for Global Health at the National Institute of Health.



---

## Viviana Galli

Coordinator, European Alliance for Responsible R&D and Affordable Medicines [@Vivivovi](#)

Since 2016 Viviana Galli coordinates the European Alliance for Responsible R&D and Affordable Medicines, an informal coalition of more than 80 patients, consumers and public health organisations across Europe. The Alliance is the first and only coalition of organisations in Europe working to call out and reduce the high prices of medicines, to promote public interest R&D financing and to foster new models of innovation.



Ms Galli has extensive experience in civil society organisations and public interest advocacy. Before joining the access to medicines field, she has been involved for several years in improving educational environments, fostering youth participation and representation and combating inequalities and discrimination. She holds a MA in European Studies from the University of Hamburg and a BA in Language and Cultural Mediation from the University of Milan.



---

## Stuart Pritchard

**Manager, European Union and Public Affairs, Wellcome Trust**  
[@wellcometrust](https://twitter.com/wellcometrust)

Stuart is Wellcome's EU & Public Affairs Manager, leading the Trust's public affairs activity with the EU institutions and a wide range of European stakeholders. Before Wellcome he worked in the charity sector for Genetic Alliance UK and the private sector, working for GlaxoSmithKline in the UK and Brussels. He spent four years in the European Parliament as Assistant to John Bowis MEP working on a number of health-related legislative dossiers.



# THE INNOVATION ECOSYSTEM IN EUROPE: HOW WILL IT LOOK LIKE IN 2025?

---

15:45-17:15



---

## Rufus Pollock

**Entrepreneur, Founder & President of Open Knowledge**

[@rufuspollock](#), [@OKFN](#)

Rufus Pollock is an entrepreneur, researcher and technologist working to create an open information age. Founder and President of Open Knowledge, a leading international non-profit that empowers people and organizations with access to information and the tools and skills to make sense of it. A recognized global expert on open data and open knowledge, he has worked with multiple governments, inter-governmental organisations such as the World Bank and the United Nations, businesses and CSOs.



---

## Jan Van den Bossche

**Partner, Fund+, Belgium**

Jan Van den Bossche holds a Masters Degree in Applied Economic Sciences at the KU Leuven. He worked for more than 12 years as a Biotech Analyst at Petercam and has been involved in numerous public and private Belgian and Dutch Biotech companies, such as ThromoboGenics, Tigenix, UCB, AMT (Uniquire), IBA and MDxHealth. Before he joined Fund+, he was part of the investor relations team at the Dutch life sciences and materials sciences company DSM (Geleen, NL) for over two years.



---

## Zoltán Kaló

**Professor of Health Economics, Eötvös Loránd University (ELTE), Hungary**

Zoltán Kaló is a Professor of Health Economics at Eötvös Loránd University (ELTE) in Budapest. He is the co-director of the international Health Policy, Planning and Financing Masters programme and the founder and leader of Syreon Research Institute. With over 20 years of international experience in academia and industry, Dr Kaló serves as a policy advisor to public decision-makers and global health care corporations. A Scientific Committee member of the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU), he was formerly a Director of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and the Chair of ISPOR Central and Eastern European Network Executive Committee between 2013-2015.



---

## Carin Uyl-de Groot

**Professor of Health Technology Assessment  
Erasmus School of Health Policy & Management, Erasmus  
University Rotterdam, The Netherlands @ESHPM\_EUR**

Carin Uyl-de Groot is Professor of Health Technology Assessment (HTA) at the Erasmus University Rotterdam. She is head of the section of HTA of the Erasmus School of Health Policy & Management and director of the institute for Medical Technology Assessment (iMTA b.v.). Her research activities are mainly focused on cost-effectiveness and outcomes studies in cancer. In 2018, Prof Uyl-de Groot was Chair of the public health and health economics track of the ESMO 2018 conference. Her paper in Nature Reviews about a new pricing model for (cancer) drugs has attracted a lot of attention.



# ACCESS TO MEDICINES RESOURCES BY EPHA AND ITS MEMBERS

---

## EUROPEAN ASSOCIATION OF HOSPITAL PHARMACISTS (EAHP)

---

EAHP's 2018 Survey on Medicines Shortages to improve patient outcomes, <http://www.eahp.eu/practice-and-policy/medicines-shortages/2018-medicines-shortage-survey>

---

## EUROPEAN AIDS TREATMENT GROUP (EATG)

---

Position paper on ensuring affordable anti-retroviral drugs, sustainable universal access to treatment, as well as continued innovation in research and development, <http://www.eatg.org/papers/position-paper-on-ensuring-affordable-anti-retroviral-drugs-sustainable-universal-access-to-treatment-as-well-as-continued-innovation-in-research-and-development/>

---

## EUROPEAN CANCER LEAGUES (ECL)

---

Let's Talk Access White Paper, <https://www.europeancancerleagues.org/wp-content/uploads/ECL-Lets-Talk-Access-White-Paper.pdf>  
CAR-T Cell Therapies: How much for survival?, [https://www.europeancancerleagues.org/wp-content/uploads/2018/06/CAR-T-ECL-Article\\_Final\\_20062018.pdf](https://www.europeancancerleagues.org/wp-content/uploads/2018/06/CAR-T-ECL-Article_Final_20062018.pdf)

---

## EUROPEAN CANCER ORGANISATION (ECCO)

---

Access to Innovation, <https://www.ecco-org.eu/Policy/Policy-Priorities/Access-to-Innovation>

---

## EUROPEAN PUBLIC HEALTH ALLIANCE (EPHA)

---

Getting it right - EPHA recommendations on the improvement of the European Commission proposal on Health Technology Assessment (HTA), <https://epha.org/epha-recommendations-ec-health-technology-assessment-hta/>

EPHA recommendations on a new model for the provision of Scientific Advice, <https://epha.org/recommendations-on-a-new-model-for-the->



[provision-of-scientific-advice/](#)

Reflection Paper | BENELUXA: First results of multi-country cooperation on medicine price negotiations, <https://epha.org/discussion-paper-beneluxa/>

EPHA Briefing | Will fast-tracking medicines improve affordability? <https://epha.org/epha-briefing-will-fast-tracking-medicines-improve-affordability/>

Scientists voice concerns about adaptive pathways, <https://epha.org/scientists-voice-concerns-about-adaptive-pathways/>

Joint declaration on access to medicines: ringing alarm bells on a deepening problem <https://epha.org/press-release-joint-declaration-on-access-to-medicines-ringing-alarm-bells-on-a-deepening-problem/>

---

## FRANCE ASSOS SANTÉ

Médicaments et progrès thérapeutique: garantir l'accès, maîtriser les prix, <http://www.france-assos-sante.org/sites/default/files/Medicaments-Livre-Blanc-Interassociatif.pdf>

Propositions d'amendements au PLFSS pour 2019, <http://www.france-assos-sante.org/sites/default/files/Propositions-Unaass-PLFSS-2019.pdf>

---

## HEALTH ACTION INTERNATIONAL (HAI)

HAI European Projects Guide 2018, <http://haiweb.org/wp-content/uploads/2018/07/HAI-EU-Work-Plan-Brochure-2018.pdf>

The way forward for access to medicines, <http://haiweb.org/wp-content/uploads/2018/05/Policy-Brief-The-Way-Forward-on-Access-to-Medicines.pdf>

Key recommendations on health technology assessments, <http://haiweb.org/wp-content/uploads/2018/06/Health-Technology-Assessments-EU-Key-Recommendations-1.pdf>

Regulating off-label use of medicines in europe, <http://haiweb.org/wp-content/uploads/2018/10/Off-label-Use-of-Medicines-in-Europe.pdf>

Drivers of irrational use of antibiotics in Europe, <http://haiweb.org/wp-content/uploads/2018/03/Report-Drivers-of-Irrational-Use-of-Antibiotics.pdf>

---

## MÉDECINS DU MONDE

"Le prix de la vie" campaign <https://www.medecinsdumonde.be/le-prix-de-la-vie-la-ministre-de-la-sant%C3%A9-re%C3%A7oit-vos-43000-signatures>

10 recommendations on Access to medicines <https://www.medecinsdumonde.be/un-symposium-attire-l%E2%80%99attention-sur-le-d%C3%A9rapage-des-prix-des-m%C3%A9dicaments-et-des->



traitements-m%C3%A9dicaments

---

## MENTAL HEALTH EUROPE (MHE)

“Shedding Light” is a project run by Mental Health Europe, which looks at transparency issues between the mental health sector and the pharmaceutical industry. <https://mhe-sme.org/shedding-light/>

---

## PRAKSIS, GREECE

PRAKSISACCESS “watchdog” website: <https://praksisaccess.org/>

Campaign video: <https://www.youtube.com/watch?v=9IKWUX9oCs4&feature=youtu.be>

Open research and medicines development call: <https://praksisaccess.org/campaign/openpharma/>

Q&A on affordable medicines concerning the situation in Greece: <https://praksisaccess.org/faq/>

On the issue with ROCHE HELLAS: <https://praksisaccess.org/campaign/praksisoscotellic/>

PRAKSIS 2017 Medical projects (access to medicines included): <https://www.youtube.com/watch?v=m-dpoETW2IM&feature=youtu.be&fbclid=IwARONIASUDyIdCYs-btqCZ9A9dvo6srgwkz3ie2cXgMVyPCJ1xANeg1JEFLM>

PRAKSIS 2016 Conference on affordability and access to medicines: <https://www.youtube.com/channel/UCXoQd1BT1MBFunnmr26sfg>

---

## ROMANIAN HEALTH OBSERVATORY

The crisis of anti-tuberculosis medicines in Romania, [http://health-observatory.ro/wp-content/uploads/2017/11/ORS\\_TB\\_report\\_2017\\_eng.pdf](http://health-observatory.ro/wp-content/uploads/2017/11/ORS_TB_report_2017_eng.pdf)

Financial relationships between the pharma & medtech industry and the Romanian medical system in 2016, <https://goo.gl/AzSmYH>

---

## WEMOS

Resources: [http://www.wemosresources.org/search/?\\_sft\\_category=medicines](http://www.wemosresources.org/search/?_sft_category=medicines)

The long arm of the pharmaceutical industry, <https://www.wemos.nl/en/the-long-arm-of-the-pharmaceutical-industry/>

Unethical clinical trials in Africa, <https://www.wemos.nl/en/unethical-clinical-trials-in-africa-2/>

EMA and Big Pharma: conflict of interests or not? <https://www.wemos.nl/en/ema-and-big-pharma-conflict-of-interests-or-not/>

UNIVERSAL ACCESS AND  
AFFORDABLE MEDICINES FORUM

20 November 2018

Scotland House, Brussels



#Trailblazers2025



European Public Health Alliance (EPHA) AISBL  
Rue de Trèves 49-51, 1040 Brussels (B) • +32 02 230 30 56  
[www.eph.org](http://www.eph.org) • [epha@epha.org](mailto:epha@epha.org) @EPHA\_EU  
Transparency Register Number: 18941013532-08